XXXX -based regimen in the treatment of refractory midline nasal/nasal-type @entity784 .

@entity1 @entity632 @entity3726 @entity784 @entity786 @entity4445 @entity619 @entity1891 @entity617
Nasal, nasal-type T-cell/natural killer cell (T/NK-cell) lymphoma is a rare disease, and its prognosis is poor. Between March 1992 and March 2002 we investigated a new @entity4445 -based salvage regimen to treat the disease and improve response to treatment and 5-year overall survival rate. Eighteen @entity1 with refractory midline nasal, nasal-type @entity784 , who were resistant to a @entity786 , @entity632 , @entity1891 , and @entity617 ( @entity3726 )-like regimen, received an @entity4445 -based salvage regimen ( @entity4445 , @entity1891 , and @entity619 ). Primary involved field radiation was given to the @entity1 after chemotherapy. Ten (55.6%) of the @entity1 achieved complete response (CR). Five @entity1 (27.8%) achieved partial response (PR). The overall response rate (CR + PR) was 83.3%. The 5-year overall survival rate was 55.6%. Results of the preliminary clinical study indicated that the @entity4445 -based salvage regimen significantly improved the response rate and 5-year survival rate. The findings suggested that the therapy is a promising new salvage regimen for treating refractory midline nasal, nasal-type @entity784 .
